文献速递妇科

晚期卵巢癌完成初始治疗后的腹腔港细胞学检查:一种「二次探查」的新方法

Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
PubMed 文献 · Gynecol Oncol · 2019-05-31

前瞻性研究分析53例晚期卵巢癌患者完成减瘤术及静脉/腹腔化疗后取出腹腔港的冲洗液细胞学,中位随访62个月。7例(13.2%)细胞学阳性,阳性组12个月内复发比例71% vs 阴性组22%(p=0.007),中位无进展生存32 vs 7个月(p=0.02),总生存84 vs 42个月(p=0.04)。作者认为该检查可预测复发和生存,可作为影像和肿瘤标志物的辅助手段。

要点

  • 53例晚期卵巢癌完成初始治疗后行腹腔港冲洗液细胞学检查,7例(13.2%)阳性。
  • 阳性组较阴性组12个月内复发比例更高:71% vs 22%(p=0.007)。
  • 阳性组中位无进展生存32 vs 7个月(p=0.02),总生存84 vs 42个月(p=0.04)。

核心结论

  • 腹腔港细胞学检查可预测卵巢癌患者的复发和生存。
  • 作者认为这一廉价检查可作为影像和肿瘤标志物的辅助手段,用于判断治疗结束时的疾病状态。
  • 作者提出进一步研究应探讨该检查如何影响疾病管理。

研究设计与样本

  • 前瞻性研究,纳入完成减瘤术及静脉/腹腔化疗后取出腹腔港的晚期卵巢癌患者。
  • 腹腔港以10 cc生理盐水冲洗入ThinPrep固定液送细胞学分析。
  • 共分析53个腹腔港冲洗液,患者中位随访62个月。
  • 生存分析采用Kaplan-Meier曲线,组间比较采用log-rank检验。

主要发现

  • 患者平均年龄58.5岁,白人占90%,3期占62%,浆液性组织学占87%。
  • 7例(13.2%)腹腔港细胞学阳性;阳性组与阴性组在年龄、BMI、分期、分级和GOG状态方面相似。
  • 阳性组复发风险HR 3.2(95%CI 0.4, 28.9),死亡风险HR 6.5(95%CI 0.7, 58.8)。
  • 阳性组较阴性组更可能在12个月内复发:71% vs 22%(p=0.007)。
  • 阳性组较阴性组中位无进展生存更短:32 vs 7个月(p=0.02);中位总生存更短:84 vs 42个月(p=0.04)。

临床怎么用

  • 作者认为该廉价检查可作为影像和肿瘤标志物的辅助手段,用于判断治疗结束时的疾病状态。
  • 作者提出进一步研究应探讨该检查如何影响疾病管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether IP port cytology predicts early recurrence and/or poor prognosis in patients with ovarian cancer who have completed primary therapy. METHODS: A prospective study of patients with advanced stage ovarian cancer undergoing IP port removal after debulking followed by IV/IP chemotherapy was performed. Ports were flushed with 10 cc of normal saline into ThinPrep fixative to be analyzed for cytology. Results were correlated with clinical factors and cancer outcomes. Survivals were calculated using Kaplan-Meier curves and compared using log-rank analysis. RESULTS: Effluent from 53 IP ports was analyzed, and patients were followed for a median of 62 months. Mean age was 58.5, with the majority of patients being white (90%), with stage 3 (62%), serous histology (87%). Seven (13.2%) patients had positive IP cytology. POS and NEG groups were similar with regard to age, BMI, stage, grade, and GOG status. Patients with POS results had increased risk of recurrence HR 3.2 (95%CI 0.4, 28.9), and death HR 6.5 (95%CI 0.7, 58.8), and were more likely to recur before 12 months, 71% vs. 22% (p = 0.007). Compared to NEG, POS conferred a shorter median survival with PFS of 32 vs. 7 months (p = 0.02) and OS of 84 vs. 42 months (p = 0.04). CONCLUSIONS: IP port cytology is predictive of recurrence and survival in patients with ovarian cancer. This inexpensive test may serve as an adjunct to imaging and tumor markers to determine disease status at the completion of treatment. Further study should investigate how this may impact management.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Grette K, Long B, Finan MA, et al. Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look". Gynecol Oncol. 2019. PMID: 31160072. doi:10.1016/j.ygyno.2019.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。